(Q53338098)

13 May 2018

title

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. (English)

1 reference

13 May 2018

author

Frauke Zipp

11

1 reference

13 May 2018

Sergiu Groppa

Sergiu Groppa

8

0 references

Stefan Bittner

Stefan Bittner

7

0 references

Amit Bar-or

10

Amit Bar-Or

1 reference

13 May 2018

Björn Tackenberg

9

Björn Tackenberg

1 reference

13 May 2018

author name string

Vinzenz Fleischer

1

1 reference

13 May 2018

Michaela Friedrich

2

1 reference

13 May 2018

Ayman Rezk

3

1 reference

13 May 2018

Ulrike Bühler

4

1 reference

13 May 2018

Esther Witsch

5

1 reference

13 May 2018

Timo Uphaus

6

1 reference

13 May 2018

Felix Luessi

12

1 reference

13 May 2018

publication date

24 April 2017

1 reference

13 May 2018

Multiple Sclerosis Journal

published in

1 reference

13 May 2018

volume

24

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

632-641

1 reference

13 May 2018

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Dimethyl fumarate associated lymphopenia in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458517703799

21 January 2018

Identifiers

DOI

10.1177/1352458517703799

1 reference

13 May 2018

PubMed ID

28436295

1 reference

13 May 2018